Genovate Biotechnology Co Ltd (4130) — Cash Flow Quality Index
Genovate Biotechnology Co Ltd (4130) has a Cash Flow Quality Index of -3.61x as of June 2025. Operating cash flow of NT$-26.50 Million is below net income of NT$7.34 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore 4130 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Genovate Biotechnology Co Ltd Cash Flow Quality Index (2015–2025)
Historical Cash Flow Quality Index for Genovate Biotechnology Co Ltd across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how tangible is Genovate Biotechnology Co Ltd's equity to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Genovate Biotechnology Co Ltd (2015–2025)
Year-by-year earnings quality comparison for Genovate Biotechnology Co Ltd. For live market cap and the full company financial profile, see 4130 stock market capitalisation.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 3.75x | NT$43.79 Million | NT$11.68 Million | ▲ +74.8% |
| 2024 | 2.14x | NT$55.11 Million | NT$25.70 Million | ▼ -25.8% |
| 2023 | 2.89x | NT$84.78 Million | NT$29.33 Million | ▲ +106.2% |
| 2021 | -46.40x | NT$-17.26 Million | NT$372.00K | ▼ -2163.6% |
| 2020 | 2.25x | NT$87.08 Million | NT$38.73 Million | ▲ +72.3% |
| 2019 | 1.30x | NT$44.43 Million | NT$34.05 Million | ▲ +20.0% |
| 2018 | 1.09x | NT$62.88 Million | NT$57.85 Million | ▲ +417.8% |
| 2017 | 0.21x | NT$31.27 Million | NT$148.97 Million | ▼ -88.3% |
| 2016 | 1.80x | NT$70.58 Million | NT$39.21 Million | ▲ +157.3% |
| 2015 | 0.70x | NT$32.53 Million | NT$46.49 Million | — |